Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

November 13, 2025 - … and the subsequent End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA); In addition, after … and the subsequent End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA); In addition, after … and the subsequent End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA); In addition, after …
News

Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

November 5, 2025 - … the subsequent End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). After receiving the data … the subsequent End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). After receiving the data … the subsequent End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). After receiving the data …
News

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

September 10, 2025 - … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 - … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 - … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025 - … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

April 30, 2025 - … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

March 20, 2025 - … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

March 11, 2025 - … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could … 2025, followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could …
News

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

January 14, 2025 - … initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort … initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort … initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort …
Scroll to Top